FOLFIRI.3 — Competitive Intelligence Brief

FOLFIRI.3 (FOLFIRI.3) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Chemotherapy regimen. Area: Oncology.

phase 2 Chemotherapy regimen Oncology Small molecule

Target snapshot

FOLFIRI.3 (FOLFIRI.3) — Federation Francophone de Cancerologie Digestive. FOLFIRI is a chemotherapy regimen that combines 5-fluorouracil, leucovorin, irinotecan, and folinic acid to target rapidly dividing cancer cells.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
FOLFIRI.3 TARGET	FOLFIRI.3	Federation Francophone de Cancerologie Digestive	phase 2	Chemotherapy regimen
Dose dense AC followed by T + trastuzumab	Dose dense AC followed by T + trastuzumab	Agendia	marketed	Chemotherapy regimen with monoclonal antibody	HER2 receptor (trastuzumab component); DNA/microtubules (chemotherapy components)
Dexamethasona, Idarubicine, ARA-C, Methotrexate	Dexamethasona, Idarubicine, ARA-C, Methotrexate	PETHEMA Foundation	marketed	Combination chemotherapy regimen
Carboplatin, Etoposide, Ifosfamide	Carboplatin, Etoposide, Ifosfamide	University Hospital Muenster	marketed	Combination chemotherapy regimen	DNA (multiple mechanisms: alkylation, cross-linking, topoisomerase II inhibition)
TCH chemotherapy	TCH chemotherapy	Agendia	marketed	Chemotherapy regimen (combination)	HER2, microtubule, DNA
CHOP-daclizumab	CHOP-daclizumab	King's College Hospital NHS Trust	marketed	Monoclonal antibody (daclizumab component) combined with chemotherapy regimen	CD25 (IL-2 receptor alpha chain)
CVP	CVP	SCRI Development Innovations, LLC	marketed	Combination chemotherapy regimen

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Chemotherapy regimen class)

1. National Research Center for Hematology, Russia · 2 drugs in this class
2. Asan Medical Center · 1 drug in this class
3. AstraZeneca · 1 drug in this class
4. CTI BioPharma · 1 drug in this class
5. Federation Francophone de Cancerologie Digestive · 1 drug in this class
6. Guiyang Medical University · 1 drug in this class
7. Japan Clinical Oncology Group · 1 drug in this class
8. PETHEMA Foundation · 1 drug in this class
9. Sixth Affiliated Hospital, Sun Yat-sen University · 1 drug in this class
10. Trans Tasman Radiation Oncology Group · 1 drug in this class